Xinying’s research focuses on engineering mRNA-LNPs to deliver a triad of immunomodulators that locally drive the recruitment, expansion, and immunogenic activation of conventional type I dendritic cells (cDC1s). This strategy aims to reconstitute a cDC1-dependent positive feedback loop between NK cells and T cells within the tumor microenvironment to overcome immune exclusion. By restoring these essential interactions, we seek to drive robust, antigen-dependent anti-tumor immunity
